view counter

BioterrorismPromising substance for better cyanide antidote for terrorist attacks

Published 31 January 2013

In an advance toward closing a major gap in defenses against terrorist attacks and other mass casualty events, scientists are reporting discovery of a promising substance that could be the basis for development of a better antidote for cyanide poisoning.

In an advance toward closing a major gap in defenses against terrorist attacks and other mass casualty events, scientists are reporting discovery of a promising substance that could be the basis for development of a better antidote for cyanide poisoning. An ACS release reports that their report, which describes a potential antidote that could be self-administered, much like the medication delivered by allergy injection pens, appears in the American Chemical Society’s (ACS) Journal of Medicinal Chemistry.

Steven E. Patterson, Ph.D., and colleagues at the University of Minnesota Center for Drug Design explain that the only existing antidotes for cyanide — recognized as a high-risk substance for potential use by terrorists — must be administered by intravenous infusion. That procedure requires highly trained paramedical personnel and takes time. Cyanide, however, is a fast-acting poison. In a situation involving mass casualties, only a limited number of victims could be saved. Patterson’s team thus sought an antidote that could be administered by intra-muscular (IM) injection, a simpler procedure that could be administered rapidly to a large number of victims or even be self-administered.

Their report describes discovery of a substance, sulfanegen TEA, “which should be amenable for development as an IM injectable antidote suitable for treatment of cyanide victims in a mass casualty setting. Further development, including efficacy in lethal cyanide animal models, will be reported at a later date.”

— Read more in Steven E. Patterson in “Cyanide Antidotes for Mass Casualties: Water-Soluble Salts of the Dithiane (Sulfanegen) from 3- Mercaptopyruvate for Intramuscular Administration,” Journal in Medical Chemistry (just accepted manuscript) (DOI: 10.1021/jm301633x)

 

view counter
view counter